ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 15, 2015, Pages 4642-4647

  Hammarén, Henrik M ^a   Ungureanu, Daniela ^a   Grisouard, Jean ^b   Skoda, Radek C ^b   Hubbard, Stevan R ^c   Silvennoinen, Olli ^a,d  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cytokine; JAK; Myeloid neoplasia; Nucleotide binding; Pseudokinase domain

Indexed keywords

ADENOSINE TRIPHOSPHATE; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE TYK2; STAT5A PROTEIN; ERYTHROPOIETIN RECEPTOR; JAK2 PROTEIN, HUMAN; PROTEIN BINDING;

ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; BINDING SITE; ENZYME ACTIVATION; ENZYME BINDING; ENZYME CONFORMATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; HUMAN; HUMAN CELL; MEAN CORPUSCULAR VOLUME; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; SIGNAL TRANSDUCTION; THERMOSTABILITY; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; ENZYMOLOGY; FEMALE; GENETICS; IMMUNOBLOTTING; METABOLISM; MISSENSE MUTATION; MOLECULAR DYNAMICS; MYELOPROLIFERATIVE DISORDER; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; ANIMALS; BINDING SITES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOBLOTTING; JANUS KINASE 2; MICE, INBRED C57BL; MOLECULAR DYNAMICS SIMULATION; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ERYTHROPOIETIN;

EID: 84928136142     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1423201112     Document Type: Article

References (40)

1. Saharinen P, Silvennoinen O (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277(49):47954-47963.
2. Chen M, et al. (2000) Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol 20(3):947-956.
3. Yeh TC, Dondi E, Uzé G, Pellegrini S (2000) A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-α signaling. Proc Natl Acad Sci USA 97(16):8991-8996.
4. Sanz Sanz A, et al. (2014) The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains. Biochim Biophys Acta 1844(10):1835-1841.
5. Lupardus PJ, et al. (2014) Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc Natl Acad Sci USA 111(22):8025-8030.
6. Saharinen P, Vihinen M, Silvennoinen O (2003) Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 14(4):1448-1459.
7. Saharinen P, Takaluoma K, Silvennoinen O (2000) Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 20(10):3387-3395.
8. Vainchenker W, Constantinescu SN (2013) JAK/STAT signaling in hematological malignancies. Oncogene 32(21):2601-2613.
9. Baxter EJ, et al.; Cancer Genome Project (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054-1061.
10. James C, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144-1148.
11. Kralovics R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779-1790.
12. Levine RL, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387-397.
13. Haan C, Behrmann I, Haan S (2010) Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med 14(3):504-527.
14. Lipson D, et al. (2012) Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18(3):382-384.
15. Candotti F, et al. (1997) Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 90(10):3996-4003.
16. Bandaranayake RM, et al. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol 19(8):754-759.
17. Ungureanu D, et al. (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 18(9):971-976.
18. Shan Y, et al. (2014) Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. Nat Struct Mol Biol 21(7):579-584.
19. Toms AV, et al. (2013) Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol 20(10):1221-1223.
20. Murphy JM, et al. (2014) A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. Biochem J 457(2):323-334.
21. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600):1912-1934.
22. Knapp S, Sundström M (2014) Recently targeted kinases and their inhibitors - The path to clinical trials. Curr Opin Pharmacol 17:58-63.
23. Fukuda K, Knight JD, Piszczek G, Kothary R, Qin J (2011) Biochemical, proteomic, structural, and thermodynamic characterizations of integrin-linked kinase (ILK): Cross-validation of the pseudokinase. J Biol Chem 286(24):21886-21895.
24. Iyer GH, Garrod S, Woods VL, Jr, Taylor SS (2005) Catalytic independent functions of a protein kinase as revealed by a kinase-dead mutant: Study of the Lys72His mutant of cAMP-dependent kinase. J Mol Biol 351(5):1110-1122.
25. Lu X, et al. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 102(52):18962-18967.
26. Lu X, Huang LJS, Lodish HF (2008) Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem 283(9):5258-5266.
27. Tiedt R, et al. (2008) Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111(8):3931-3940.
28. Zeqiraj E, et al. (2009) ATP and MO25α regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor. PLoS Biol 7(6):e1000126.
29. Littlefield P, Moasser MM, Jura N (2014) An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Chem Biol 21(4):453-458.
30. Cameron AJ, Escribano C, Saurin AT, Kostelecky B, Parker PJ (2009) PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat Struct Mol Biol 16(6):624-630.
31. Lange A, et al. (2009) Integrin-linked kinase is an adaptor with essential functions during mouse development. Nature 461(7266):1002-1006.
32. Andraos R, et al. (2012) Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov 2(6):512-523.
33. Gu J, Wang Y, Gu X (2002) Evolutionary analysis for functional divergence of Jak protein kinase domains and tissue-specific genes. J Mol Evol 54(6):725-733.
34. Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN (2010) JAK2 V617F constitutive activation requires JH2 residue F595: A pseudokinase domain target for specific inhibitors. PLoS ONE 5(6):e11157.
35. Gnanasambandan K, Magis A, Sayeski PP (2010) The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617. Biochemistry 49(46):9972-9984.
36. Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM (2009) Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326(5960):1707-1711.
37. Scheeff ED, Eswaran J, Bunkoczi G, Knapp S, Manning G (2009) Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17(1):128-138.
38. Sonbol MB, et al. (2013) Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol 4(1):15-35.
39. Humphrey W, Dalke A, Schulten K (1996) VMD: Visual molecular dynamics. J Mol Graph 14(1):33-38, 27-28.
40. Niranjan Y, et al. (2013) Analysis of steady-state Förster resonance energy transfer data by avoiding pitfalls: Interaction of JAK2 tyrosine kinase with N-methylanthraniloyl nucleotides. Anal Biochem 442(2):213-222.